



# Prenatal Chlamydia & Gonorrhea Screening



SUNNYBROOK OBGYN PGY1S

SARA PORISKY, EMMA SKOLNIK,  
JESSICA SMITH, GEOFF ZENI,  
REBECCA ZUR

SUPERVISOR: DR. ANDREA PAGE



# Current Guidelines

- ▶ Public Health Agency of Canada recommends:
  - ▶ All pregnant women should be screened for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (GC)
  - ▶ All pregnant women should be evaluated for STI risk factors prior to and during pregnancy
  - ▶ If an STI is diagnosed in pregnancy, treatment specific to the disease should be initiated
  - ▶ Follow-up after treatment of STIs for both the patient and her sexual partner(s) to ensure therapeutic success

# Background



- ▶ STIs in pregnancy associated with adverse outcomes: (Aggarwal *et al.*, 2010)
  - ▶ Spontaneous abortion
  - ▶ Preterm labour
  - ▶ Congenital infections
  - ▶ Postpartum endometritis
  
- ▶ Suggested move away from Routine Neonatal Ocular Prophylaxis (Poliquin *et al.*, 2016)

# Background



- ▶ Suboptimal rates of testing in Canada (Poliquin *et al.*, 2016)
- ▶ Suboptimal rates of testing reported in Toronto (Vainder, Kives & Yudin, 2017):
  - ▶ 15% of women not tested for gonorrhea and chlamydia during pregnancy
  - ▶ 11 cases of Chlamydia
  - ▶ Testing rates by specialty:
    - ▶ Midwifery (93.8%)
    - ▶ Family Practice OB (91.4%)
    - ▶ General OB (88.5%)
    - ▶ MFM (64.9%)



# Initial Aim Statement

- ▶ *Our aim is to improve the proportion of prenatal patients delivering at Sunnybrook Health Sciences Centre screened for chlamydia and gonorrhoea at or before 36 weeks gestational age from 50% to 80% by May 1, 2017.*



# Pre-intervention data

- ▶ Inclusion criteria:
  - ✓ Obstetrical patients who presented to SHSC L&D triage between March 1 and March 7, 2017
  - ✓  $\geq 36$  weeks gestational age
  - ✓ Prenatal records available from office or through PRO
  - ✓ Followed by a OBGYN at Sunnybrook for prenatal care through low risk or high risk obstetrics clinics
  
- ▶ Sample of 125 patients analyzed

# Pre-intervention analysis



**Chlamydia (CT) screening rate: 73%**

**Gonorrhea (GC) screening rate: 72%**

- ▶ A preliminary screen of antenatal records revealed a screening rate of 51%
- ▶ Of the sample analyzed, no patients were positive for GC/CT



# Revised Aim Statement

- ▶ *Our aim is to improve the proportion of prenatal patients delivering at Sunnybrook Health Sciences Centre screened for chlamydia and gonorrhoea at or before 36 weeks gestational age from 72.5% to 90% by Dec 1, 2017.*



# Intervention




- ▶ All obstetricians offering prenatal care through Sunnybrook were contacted in person to discuss our aim of a standardized time of testing for GC/CT



# Initial outcomes

- ▶ Possible testing times discussed:
  - ▶ Initial visit with provider
  - ▶ 28 weeks at time of OGTT
  - ▶ 35-37 weeks at time of GBS testing
  
- ▶ Conclusions following discussion with staff:
  - ▶ First antenatal visit is the ideal time for GC/CT testing for most providers
    - ▶ Ensures testing for those who deliver prematurely
    - ▶ Later time points likely will cause duplicate orders and added cost to the system. Many physicians order urine CT/GC during the first trimester.

# Initial Outcomes



- ▶ We proposed adding GC/CT urine testing to first antenatal bloodwork requisition for all staff at Sunnybrook.
- ▶ 14/16 providers already had a standardized testing time point, and were supportive of this initiative
- ▶ Remaining 2 providers were agreeable to adding GC/CT urine testing to their initial antenatal bloodwork requisition
- ▶ We will also announce this QI change idea at Grand Rounds to consolidate dissemination and optimize buy-in.



# Outcome follow up

- ▶ Women being screened for GC/CT at first prenatal visit will be reaching  $\geq 36$  weeks gestation in December 2017.
- ▶ We will perform another random sampling of triage patients over the span of one week in December 2017.
- ▶ Goal: Increase in GC/CT screening rate from 72% to >90%

# Stewardship



- ▶ Importance of recording bloodwork results on antenatal records
- ▶ Cost-benefit

# Benefits




- ▶ Fostering conversation amongst staff about the importance of EBM guidelines for prenatal screening



# Limitations

- ▶ Small sample size
- ▶ No analysis of heterogeneity of sample



# QI Reflections

- ▶ Routine reflection and re-evaluation required
- ▶ Change management requires diffuse buy-in





# References

- ▶ Public Health Agency of Canada (2013). Canadian Guidelines on Sexually Transmitted Infections: Section 6 – Specific Populations – Pregnancy: Retrieved May 16 2017 from <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-6-4-eng.php>
- ▶ Aggarwal et al (2010) Repeat Screening for Sexually Transmitted Infection in Adolescent Obstetric Patients, *Journal of Obstetrics and Gynaecology Canada*, 2010; 32(10): 956-961.
- ▶ Vainder, M., Kives, S. & Yudin, M. (2017) P-OBS-JM-032 Rates of Gonorrhoea and Chlamydia Testing Among Pregnant Women Presenting for Prenatal Care [Conference Abstract]. *Journal of Obstetrics and Gynaecology Canada*, 2017; 39(5):404.
- ▶ Poliquin, V., Wylie, J., Cole, R., Yudin, M. & Van Caesseele, P. (2016). Preparedness for implementing Change in Neonatal Ocular Prophylaxis Policies. *Journal of Obstetrics and Gynaecology Canada*, 2016; 38(1):7-8.

# The Clap!

